EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release.
Suh KJ, Sung JH, Kim JW, Han SH, Lee HS, Min A, Kang MH, Kim JE, Kim JW, Kim SH, Lee JO, Kim YJ, Lee KW, Kim JH, Bang SM, Im SA, Lee JS.
Suh KJ, et al.
Oncotarget. 2017 Jul 12;8(38):63901-63910. doi: 10.18632/oncotarget.19194. eCollection 2017 Sep 8.
Oncotarget. 2017.
PMID: 28969039
Free PMC article.